Taysha Gene Therapies, Inc. Interest Income (Expense), Nonoperating, Net
Taysha Gene Therapies, Inc. (TSHA) reported Interest Income (Expense), Nonoperating, Net of $1.44 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-12.
Discontinued › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNonoperatingNet · last filed 2024-08-12
- Taysha Gene Therapies, Inc. interest income (expense), nonoperating, net for the quarter ending 2024-06-30 was $1.44M, a 545.74% increase year-over-year.
- Taysha Gene Therapies, Inc. interest income (expense), nonoperating, net for the quarter ending 2024-03-31 was $1.69M, a 430.72% increase year-over-year.
- Taysha Gene Therapies, Inc. interest income (expense), nonoperating, net for the quarter ending 2023-12-31 was $1.92M, a 865.33% increase year-over-year.
- Taysha Gene Therapies, Inc. interest income (expense), nonoperating, net for the quarter ending 2023-09-30 was $1.11M, a 12222.22% increase year-over-year.
- Taysha Gene Therapies, Inc. interest income (expense), nonoperating, net for fiscal 2023 was $3.57M, a 1334.54% increase from fiscal 2022.
- Taysha Gene Therapies, Inc. interest income (expense), nonoperating, net for fiscal 2022 was $249.00K, a 44.77% increase from fiscal 2021.
- Taysha Gene Therapies, Inc. interest income (expense), nonoperating, net for fiscal 2021 was $172.00K, a 251.02% increase from fiscal 2020.
- Taysha Gene Therapies, Inc. interest income (expense), nonoperating, net for fiscal 2020 was $49.00K.
| Period end | Interest Income (Expense), Nonoperating, Net 3 month | Interest Income (Expense), Nonoperating, Net 6 month | Interest Income (Expense), Nonoperating, Net 9 month | Interest Income (Expense), Nonoperating, Net 12 month |
|---|---|---|---|---|
| 2024-06-30 | $1.44M 10-Q · filed 2024-08-12 | $3.13M 10-Q · filed 2024-08-12 | $5.05M derived: sum of 3 quarters · filed 2024-08-12 | $6.16M derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | $1.69M 10-Q · filed 2024-05-14 | $3.61M derived: sum of 2 quarters · filed 2024-05-14 | $4.72M derived: sum of 3 quarters · filed 2024-05-14 | $4.95M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-12-31 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $3.03M derived: sum of 2 quarters · filed 2024-03-19 | $3.25M derived: sum of 3 quarters · filed 2024-08-12 | $3.57M 10-K · filed 2024-03-19 |
| 2023-09-30 | $1.11M 10-Q · filed 2023-11-14 | $1.33M derived: sum of 2 quarters · filed 2024-08-12 | $1.65M 10-Q · filed 2023-11-14 | $1.85M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-06-30 | $223.00K 10-Q · filed 2024-08-12 | $542.00K 10-Q · filed 2024-08-12 | $741.00K derived: sum of 3 quarters · filed 2024-08-12 | $750.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $319.00K 10-Q · filed 2024-05-14 | $518.00K derived: sum of 2 quarters · filed 2024-05-14 | $527.00K derived: sum of 3 quarters · filed 2024-05-14 | $554.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $199.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $208.00K derived: sum of 2 quarters · filed 2024-03-19 | $235.00K derived: sum of 3 quarters · filed 2024-03-19 | $249.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | $9.00K 10-Q · filed 2023-11-14 | $36.00K derived: sum of 2 quarters · filed 2023-11-14 | $50.00K 10-Q · filed 2023-11-14 | $79.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $27.00K 10-Q · filed 2023-08-14 | $41.00K 10-Q · filed 2023-08-14 | $70.00K derived: sum of 3 quarters · filed 2023-08-14 | $107.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $14.00K 10-Q · filed 2023-05-11 | $43.00K derived: sum of 2 quarters · filed 2023-05-11 | $80.00K derived: sum of 3 quarters · filed 2023-05-11 | $120.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $66.00K derived: sum of 2 quarters · filed 2023-03-28 | $106.00K derived: sum of 3 quarters · filed 2023-03-28 | $172.00K 10-K · filed 2023-03-28 |
| 2021-09-30 | $37.00K 10-Q · filed 2022-11-08 | $77.00K derived: sum of 2 quarters · filed 2022-11-08 | $143.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $40.00K 10-Q · filed 2022-08-11 | $106.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $66.00K 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $49.00K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |